Eric Van Cutsem, MD, PhD

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

Eric Van Cutsem , MD, PhD;

07/01/2019

KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study

Background Microsatellite stable/mismatch repair proficient (MSS/MMRp) stage IV colorectal cancer (CRC) remains an area of high unmet medical need, with the vast majority not responding t...

Eric Van Cutsem , MD, PhD;

07/01/2021

Multidisciplinary Tumor Board: A Challenging Patient With Colorectal Cancer

Josep Tabernero , MD, PhD;

Thomas Gruenberger , MD;

Sharlene Gill , MD, MPH, MBA, FRCPC;

Michel P. Ducreux , MD, PhD;

Eric Van Cutsem , MD, PhD;

Axel Grothey , MD;

07/19/2019

A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers

Background Activation of the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2) induces apoptosis via the extrinsic pathway. Targeting TRAILR2 ...

Eric Van Cutsem , MD, PhD;

06/27/2022

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

Eric Van Cutsem , MD, PhD;

07/01/2019

Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs

Background In the primary analysis of the phase 3 NETTER-1 trial, 177Lu-DOTATATE significantly prolonged progression-free survival (PFS) versus high-dose long-acting octreotide, with a HR...

Eric Van Cutsem , MD, PhD;

07/01/2021

This Clinical Research Update expands on the earlier oral abstract presentation by Dr. Bekaii-Saab, and features an investigator-led discussion of both the significance of the research findings and the practice-changing potential of the data.

Tanios Bekaii-Saab , MD, FACP;

Eric Van Cutsem , MD, PhD;

07/10/2018

Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)

Background The BRAF V600E mutation is associated with the hypermethylator phenotype CIMP, which can also lead to the MSI-H phenotype. BRAF V600E mutation and MSI-H/dMMR status seem to be...

Eric Van Cutsem , MD, PhD;

07/02/2022

MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)

Background The clinical benefit of approved therapies in patients (pts) with metastatic colorectal cancer (mCRC) who progress on first- and second-line chemotherapy (FOL...

Eric Van Cutsem , MD, PhD;

06/28/2021

Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies

Background The KRAS G12C inhibitor sotorasib has shown promising anticancer activity in patients with advanced solid tumors harboring the KRAS G12C mutation, holding the potential for tra...

Eric Van Cutsem , MD, PhD;

07/02/2021